Optimizing Treatment Strategies in Patients With Polycythemia Vera Who Develop a Thrombotic Event on Frontline Therapy
Lindsey Lyle,(1) MS, PA-C, and Julie Huynh-Lu,(2) PA
From (1)University of Colorado Cancer Center, Aurora, Colorado; (2)The University of Texas MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Lindsey Lyle, MS, PA-C,
University of Colorado, 1665 Aurora Court, Aurora, CO 80045.
J Adv Pract Oncol 2020;11(Suppl 2):20–26 |
© 2020 Harborside™
Advanced practitioners are ideal advocates for their patients with polycythemia vera who have had a thrombotic event to ensure that secondary prevention measures are in place, including the implementation of close monitoring and tailoring therapy to meet individual needs. Being equipped with the medical knowledge to identify patients who are displaying signs and symptoms of resistance or intolerance is key to minimizing disease- or therapy-related complications and ultimately provide personalized therapy for each patient.
For access to the full length article, please sign in